{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:36:37Z","timestamp":1754163397879,"version":"3.41.2"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10637-024-01498-0","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T23:14:39Z","timestamp":1746054879000},"page":"602-608","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An investigation of extended-interval dosing of atezolizumab in Japanese patients with advanced solid tumors: safety and pharmacokinetics of a dose of 1680\u00a0mg every 4 weeks"],"prefix":"10.1007","volume":"43","author":[{"given":"Shunsuke","family":"Kondo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigehisa","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Katsuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Mizugaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ippei","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichiro","family":"Iwasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuki","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chika","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"issue":"9","key":"1498_CR1","doi-asserted-by":"publisher","first-page":"e44582","DOI":"10.7759\/cureus.44582","volume":"15","author":"A Abaza","year":"2023","unstructured":"Abaza A, Sid Idris F, Anis Shaikh H, Vahora I, Moparthi KP, Al Rushaidi MT, Muddam MR, Obajeun OA, Jaramillo AP, Khan S (2023) Programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immunotherapy: a promising breakthrough in cancer therapeutics. Cureus 15(9):e44582. https:\/\/doi.org\/10.7759\/cureus.44582","journal-title":"Cureus"},{"issue":"5","key":"1498_CR2","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O\u2019Byrne K, Kulasinghe A (2022) Immune checkpoint inhibitors in cancer therapy. Curr Oncol 29(5):3044\u20133060. https:\/\/doi.org\/10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"issue":"6","key":"1498_CR3","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00280-019-03954-8","volume":"84","author":"KM Morrissey","year":"2019","unstructured":"Morrissey KM, Marchand M, Patel H, Zhang R, Wu B, Phyllis Chan H, Mecke A, Girish S, Jin JY, Winter HR, Bruno R (2019) Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemother Pharmacol 84(6):1257\u20131267. https:\/\/doi.org\/10.1007\/s00280-019-03954-8","journal-title":"Cancer Chemother Pharmacol"},{"issue":"24","key":"1498_CR4","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-12-1362","volume":"18","author":"DS Chen","year":"2012","unstructured":"Chen DS, Irving BA, Hodi FS (2012) Molecular pathways: next-generation immunotherapy\u2013inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 18(24):6580\u20136587. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1362","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1498_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1):1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"issue":"6","key":"1498_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.cllc.2019.07.005","volume":"20","author":"M Nishio","year":"2019","unstructured":"Nishio M, Sugawara S, Atagi S, Akamatsu H, Sakai H, Okamoto I, Takayama K, Hayashi H, Nakagawa Y, Kawakami T (2019) Subgroup analysis of Japanese patients in a phase III study of atezolizumab in extensive-stage small-cell lung cancer (IMpower133). Clin Lung Cancer 20(6):469\u2013476e1. https:\/\/doi.org\/10.1016\/j.cllc.2019.07.005","journal-title":"Clin Lung Cancer"},{"key":"1498_CR7","unstructured":"Chugai News release. Chugai obtains approval for additional indication of Tecentriq and Avastin as the first cancer immunotherapy for unresectable hepatocellular carcinoma. https:\/\/www.chugai-pharm.co.jp\/english\/news\/detail\/20200925153000_767.html. Accessed 8 July 2024"},{"issue":"12","key":"1498_CR8","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1111\/cas.15564","volume":"113","author":"H Kenmotsu","year":"2022","unstructured":"Kenmotsu H, Sugawara S, Watanabe Y, Saito H, Okada M, Chen-Yoshikawa TF, Ohe Y, Nishio W, Nakagawa S, Nagao H (2022) Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010). Cancer Sci 113(12):4327\u20134338. https:\/\/doi.org\/10.1111\/cas.15564","journal-title":"Cancer Sci"},{"key":"1498_CR9","unstructured":"Pharmaceuticals and Medical Devices Agency Review report (Tecentriq). https:\/\/www.pmda.go.jp\/files\/000235287.pdf. Accessed 8 July 2024"},{"key":"1498_CR10","unstructured":"Chugai News release. Chugai launches Tecentriq intravenous infusion 840\u00a0mg as an optimal formulation for the treatment of PD-L1-positive inoperable or metastatic triple negative breast cancer. https:\/\/www.chugai-pharm.co.jp\/english\/news\/detail\/20191127100000_671.html. Accessed 8 July 2024"},{"key":"1498_CR11","unstructured":"TECENTRIQ\u00ae (atezolizumab) Prescribing information (ed) (2024)"},{"key":"1498_CR12","unstructured":"TECENTRIQ\u00ae (atezolizumab) Summary of product characteristics (ed) (2024)"},{"issue":"4","key":"1498_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1001\/jamaoncol.2017.5440","volume":"4","author":"DP Petrylak","year":"2018","unstructured":"Petrylak DP, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R, Vogelzang NJ (2018) Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer. JAMA Oncol 4(4):537\u2013544. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5440","journal-title":"JAMA Oncol"},{"issue":"5","key":"1498_CR14","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s10637-016-0371-6","volume":"34","author":"H Mizugaki","year":"2016","unstructured":"Mizugaki H, Yamamoto N, Murakami H, Kenmotsu H, Fujiwara Y, Ishida Y, Kawakami T, Takahashi T (2016) Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. Invest New Drugs 34(5):596\u2013603. https:\/\/doi.org\/10.1007\/s10637-016-0371-6","journal-title":"Invest New Drugs"},{"issue":"3","key":"1498_CR15","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/19420862.2015.1136043","volume":"8","author":"R Deng","year":"2016","unstructured":"Deng R, Bumbaca D, Pastuskovas CV, Boswell CA, West D, Cowan KJ, Chiu H, McBride J, Johnson C, Xin Y, Koeppen H, Leabman M, Iyer S (2016) Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs 8(3):593\u2013603. https:\/\/doi.org\/10.1080\/19420862.2015.1136043","journal-title":"MAbs"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01498-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01498-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01498-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T04:05:39Z","timestamp":1753934739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01498-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1498"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01498-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki (Japan Medical Association translation), the Act on the Protection of Personal Information, and the Ethical Guidelines for Medical and Health Research Involving Human Subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All enrolled patients received a full explanation of the contents of this clinical research and provided written consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Ippei Miyamoto declared no financial and non-financial disclosures. Shunshuke Kondo reported honoraria from ONO, AstraZeneca K.K, TAIHO, Daiichi Sankyo, Eisai, and Chugai; payment for expert testimony from Cmic, SHIONOGI & CO, and Sanofi K.K; participation on a Data Safety Monitoring Board or Advisory Board from Cmic Co and SHIONOGI & CO. Shigehisa Kitano reported support for this manuscript from Chugai; grants from Chugai, Eisai, Astellas, Takara Bio, Pfizer, Incyte, Takeda, Eli Lilly\/LOXO, Merck KGaA, Ono, Boehringer Ingelheim, Daiichi Sankyo, MSD, Astra Zeneca, Abbvie, GSK, and Kyowa Kirin: consulting fees from Chugai, Astra Zeneca, GSK, ImmuniT Research, Astellas, Ono, Sumitomo Pharma, Rakuten Meidical, United Immunity, and Kyowa Kirin; honoraria from Chugai, Ono MSD, Boehringer Ingelheim, Eizai, Eli Lilly, Daiichi Sankyo, Takeda, Bristol-Myers Squibb, AstraZeneca, Pfizer, Taiho, GSK, Novartis, Astellas, and Merck KGaA. Jun Sato reported honoraria from Eisai, Chugai and Fuji Film. Yuki Katsuya reported support from Ono Pharma for attending meetings. Takahiro Kogawa reported consulting fees from Daiichi Sakyo and Astellas Pharma; honoraria from Daiichi Sakyo, Eisai, Ono, Astra Zeneca, Gilead Sciences, Taiho Pharma, Astellas Pharma, and Chugai; Payment for expert testimony from Astellas Pharma; support for attending meetings from Phyzer and Eisai; participation on a Data Safety Monitoring Board or Advisory Board from Daiichi Sakyo, Eisai, Ono, Astra Zeneca, Gilead sciences, Taiho, Oncotherapy Sciences; receipt of services from Daiichi Sakyo. Hidenori Mizugaki reported honoraria from Chugai, Daiichi Sankyo, AstraZeneca K.K, Takeda, and Merck. Hiroaki Tomita, Tatsuki Imaizumi and Chika Murakami reported employment and stocks owned at Chugai. Shunichiro Iwasawa and Takeshi Miyake reported employment at Chugai. Noboru Yamamoto reported grants from Astellas, Chugai, Eisai, Taiho, BMS, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi-Sankyo, Bayer, Boehringer Ingelheim, Kyowa Kirin, Takeda, ONO, Janssen Pharma, MSD, MERCK, GSK, Sumitomo Pharma, Chiome Bioscience, Otsuka, Carna Biosciences, Genmab, Shionogi, TORAY, KAKEN, AstraZeneca, Cmic, InventisBio, Rakuten Medical, Amgen, and Bicycle Therapeutics; consulting fees received from Eisai, Takeda, Boehringer Ingelheim, Cmic, Chugai, MERCK, Healios, and Noile-Immune Biotech; honoraria as a speaker from Chugai, Daiichi-Sankyo, and Eisai.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}